{
    "table_name": "quant_phosphoproteome_AML_ex_vivo_drug_response_sorafenib_treatment_pdc_current",
    "table_fullname": "isb-cgc-bq.CPTAC.quant_phosphoproteome_AML_ex_vivo_drug_response_sorafenib_treatment_pdc_current",
    "column_names": [
        "case_id",
        "sample_id",
        "aliquot_id",
        "aliquot_submitter_id",
        "aliquot_run_metadata_id",
        "study_name",
        "protein_abundance_log2ratio",
        "refseq_id",
        "phosphorylation_sites"
    ],
    "column_types": [
        "STRING",
        "STRING",
        "STRING",
        "STRING",
        "STRING",
        "STRING",
        "FLOAT64",
        "STRING",
        "STRING"
    ],
    "nested_column_names": [
        "case_id",
        "sample_id",
        "aliquot_id",
        "aliquot_submitter_id",
        "aliquot_run_metadata_id",
        "study_name",
        "protein_abundance_log2ratio",
        "refseq_id",
        "phosphorylation_sites"
    ],
    "nested_column_types": [
        "STRING",
        "STRING",
        "STRING",
        "STRING",
        "STRING",
        "STRING",
        "FLOAT64",
        "STRING",
        "STRING"
    ],
    "description": [
        "Unique identifier associated with a specific patient (e.g. 24cb0fcb-63d6-11e8-bcf1-0a2705229b82)",
        "Unique PDC identifier for this sample (e.g. e8d83eb9-693a-11ea-b1fd-0aad30af8a83)",
        "Unique PDC identifier for this aliquot (e.g. e8db124a-693a-11ea-b1fd-0aad30af8a83)",
        "Aliquot submitter id assigned by program (e.g. T14)",
        "Uniquely identifies the aliquot by how it was used in the experiment (based on the labelling reagent and/or biological replicate)",
        "Name of the study (e.g. Pediatric Brain Cancer Pilot Study - Phosphoproteome)",
        "Average log-ratio of sample reporter-ion to common reference of peptide ions associated with the gene in acquisitions from a specific biological sample",
        "Unique identifier given to a sequence in the NCBI RefSeq database",
        "Single letter codes and protein sequence positions of the phosphorylated amino acids (e.g. t304s310, t59)"
    ],
    "sample_rows": [
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -2.4666,
            "refseq_id": "NP_000436.2",
            "phosphorylation_sites": "s1622"
        },
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -4.905,
            "refseq_id": "NP_000923.1",
            "phosphorylation_sites": "s537"
        },
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -4.0065,
            "refseq_id": "NP_001001.2",
            "phosphorylation_sites": "s235s236"
        },
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -3.9549,
            "refseq_id": "NP_001005751.1",
            "phosphorylation_sites": "s1114"
        },
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -3.2762,
            "refseq_id": "NP_001007027.1",
            "phosphorylation_sites": "s739s746s748"
        }
    ]
}